Novartis announced that it plans to buy Fougera – a specialist in non-branded dermatology medicines - for $1.5bn earlier this week, explaining that the plan is to combine the firm with its existing Sadoz generic drug unit.
Sandoz global head Jeff George said: “The addition of Fougera's leading portfolio further strengthens Sandoz's differentiated products strategy and improves our ability to help patients and customers around the world by providing easier access to high quality, affordable dermatological medicines.
He added that: HeHh“Fougera brings us valuable technical capabilities in the area of topical dermatological products, particularly in the development and manufacturing of semi-solid forms such as creams and ointments.”